Mosaic chemotherapy strategies for developing ALS/MND therapeutic approaches: Beta-2 adrenergic agonists.

Authors :: Brooks, B R
Juhasz-Poscine, K
Waclawik, A
Sanjak, M
Belden, D
Roelke, K
Parnell, J
Weasler, C
Source :: Amyotrophic Lateral Sclerosis & Other Motor Neuron Disorders. Dec2000 Supplement 4, Vol. 1, p45-54. 10p.
Publication Year :: 2000
Abstract: Explores strategies to develop mosaic chemotherapeutic approaches for amyotrophic lateral sclerosis/motor neurone disease (ALS/MND). Inclusion of beta-2 adrenergic agonists for ALS/MND treatment; Pathogenesis-based and symptom-directed therapies in ALS/MND; Effect of beta-2 adrenergic agonists in the central nervous system and muscular system; Side-effects of beta-2 adrenergic agonists.

Subjects :: *AMYOTROPHIC lateral sclerosis treatment
*ADRENERGIC beta agonists

Full Text Access

Tools